Immunotherapy of lung cancer: An update

Onkologie

Volumn 29, Issue 1-2, 2006, Pages 33-38

  Rüttinger, Dominik ^a,g   Winter, Hauke ^a   Van Den Engel, Natasja K ^a   Hatz, Rudolf A ^a   Schlemmer, Marcus ^b   Pohla, Heike ^c,e   Grützner, Stefanie ^d   Schendel, Dolores J ^e   Fox, Bernard A ^f   Jauch, Karl Walter ^a  

^a Chirurgische Klinik und Poliklinik   (Germany)

^b Medizinische Klinik III   (Germany)

^c Labor für Tumorimmunologie   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f EARLE A CHILES RESEARCH INSTITUTE   (United States)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunotherapy; Lung cancer; Vaccines

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; BCG VACCINE; BLP 25; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GVAX; INTERLEUKIN 17; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; MITUMOMAB; MUCIN 1; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; THYMOSIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE MUTATION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOSTIMULATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; ONCOGENE RAS; OVERALL SURVIVAL; REVIEW; SUICIDE GENE THERAPY; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS VECTOR;

CANCER VACCINES; CLINICAL TRIALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS;

EID: 33644762961     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090341     Document Type: Review

References (40)

1. Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER: Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther 2003;10:850-858.
2. Millar JW, Roscoe P, Pearce SJ, Ludgate S, Horne NW: Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax 1982;37:57-60.
3. Bast RC, Zbar B, Borsos T, Rapp HJ: BCG and cancer. N Engl J Med 1974;290:1458-1469.
4. O'Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, Ryan C, Priest K, Bromelov KV, Palmer RD, Tuckwell N, Kennard DA, Souberbielle BE: A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853-857.
5. Anthony HM, Mearns AJ, Mason MK, Scott DG, Moghissi K, Deverall PB, Rozycki ZJ, Watson DA: Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 1979;34:4-12.
6. Cohen MH, Chretien PB, Ihde DC, Fossieck BE, Makuch R, Bunn PA, Johnston AV, Shackney SE, Matthews MJ, Lipson SD, Kenady DE, Minna JD: Thymosine fraction V and intensive combination chemotherapy. JAMA 1979;241:1813-1815.
7. Agarwala SS: Interferon-alpha and -beta: clinical applications; in Rosenberg SA (ed): Principles and Practice of the Biologic Therapy of Cancer. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 275-285.
8. Aman MJ, Stockdreher K, Thews A, Kienast A, Aulitzky WE, Farber L, Haus U, Koci B, Huber C, Peschel C: Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor in vivo. Ann Hematol 1996;73:231-238.
9. Bermers AJA, Parmiani G: Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000;34:1-25.
10. Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yoshino I, Sugimachi K: Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 1999;26:143-148.
11. Kimura H, Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-49.
12. Kimura Y, Yamaguchi Y: Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer. Lung Cancer 1996;14:301-314.
13. Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML, Lallot C, Eber M, Bartholeyns J, Poindron P: Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol 1991;33:319-326.
14. Carbone FR, Bevan MJ: Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 1990;171:377-387.
15. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC: Loss of antigen-presenting molecules (MHC class I and TAP-I) in lung cancer. Br J Cancer 1996;73:148-153.
16. Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT: Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987;24:76-85.
17. Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, Reggiardo G, Morasso G, Santi L, Moretta L: Treatment of stage IIIb NSCLC with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother Emphasis Tumor Immunol 1996;19:224-230.
18. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilinia R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non small cell lung carcinoma. Cancer 1996;78:244-251.
19. Chan B, Lee W, Hu CXL, Ng P, Li KW, Lo G, Ho G, Yeung DW, Woo D: Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study. Cytotherapy 2003;5:46-54.
20. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morto KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
21. Dranoff G, Jaffee E, Lazenbay A: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
22. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. J Clin Oncol 2003;21:624-630.
23. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, Hamilton S, Borellini S, Lin A, Morali S, Hege K: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-331.
24. Ma J, Poehlein CH, Jensen S, Lacelle MG, Moudgil TM, Rüttinger D, Haley D, Goldstein M, Smith III JW, Curti B, Ross H, Walker E, Hu HM, Urba WJ, Fox BA: Manipulating the host response to autologous tumor vaccines. Dev Biol (Basel) 2004;116:93-107.
25. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M: Phase I study of the BLP25 (MUC1 Peptide) liposomale vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57.
26. Gotoh K, Yatabe Y, Sugiura T, Takagi K, Ogawa M, Takahashi T, Mitsudomi T: Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer 1998;20:117-125.
27. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffmann EW, Ritter G, Old LJ, Gnjatic S: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004;172:3289-3296.
28. Grant SC, Kris MG, Houghton AN, Chapman PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus calmette-guerin. Clin Cancer Res 1999;5:1319-1323.
29. Smith A, Justin T, Michaeli D, Watson SA: Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 2000;6:4719-4724.
30. Nikitina E, Clark J, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI: Dendritic cells transduced with full-length wild-type p53 generate anti-tumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;1:2-4.
31. Dickler M, Ragupathi G, Liu N, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC: Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 1999;5:2773-2779.
32. Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO: Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004;10:6094-6100.
33. Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO: Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004;10:916-923.
34. Marshall JL, Arlen PM, Rizvi N: A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas. Proc Am Soc Clin Oncol 2002;21:7a.
35. Swisher S, Roth J: Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin North Am 2002;11:521-535.
36. Roth JA, Grammer SF: Gene replacement therapy for non-small cell lung cancer: a review. Hematol Oncol Clin N Am 2004;18:215-229.
37. Sterman D, Treat J, Litzky L: Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothehoma. Hum Gene Ther 2000;9:1083-1092.
38. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P: Gene-based vaccines and immunotherapeutics. PNAS 2004;101:14567-14571.
39. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-2407.
40. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, George S, Leonardo J, McCachren S, Miller GL, Modiano M, Valdivieso M, Geary R, Oliver JW, Holmlund J: A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-α, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:6086-6093.